In Vitro Activity and Synergism of Amphotericin B and the Synthetic Bioinspired Peptide γ31-45PvD₁⁺⁺ Against Fungal Study Models Candida tropicalis and Saccharomyces cerevisiae.
- 1Laboratório de Fisiologia e Bioquímica de Microrganismos, Centro de Biociências e Biotecnologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, 28013-602, Brazil.
- 2Laboratório de Biologia Celular e Tecidual, Centro de Biociências e Biotecnologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, 28013-602, Brazil.
- 3Laboratório de Fisiologia e Bioquímica de Microrganismos, Centro de Biociências e Biotecnologia, Universidade Estadual do Norte Fluminense Darcy Ribeiro, Campos dos Goytacazes, RJ, 28013-602, Brazil. [email protected].
Abstract
In recent years, following the COVID-19 pandemic, the emergence of antibiotic-resistant microorganisms has increased. This surge has prompted global research into new biologically active molecules, particularly those focused on combination therapies involving antifungal agents. Synthetic antimicrobial peptides have emerged as promising candidates to address this demand. Therefore, the objective of this study was to assess the synergistic therapeutic effects of the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ combined with amphotericin B (AmB) on Candida tropicalis and Saccharomyces cerevisiae. This study aimed to identify the synergistic concentration that could facilitate advancement in the development of novel drugs. Here, we demonstrated that synergistic combinations of synthetic peptides and amphotericin B (AmB) effectively induce cell death in C. tropicalis and S. cerevisiae. The checkerboard test revealed synergistic concentrations of 0.048 µM for AmB, 0.39 µM for the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ for C. tropicalis, 0.097 µM for AmB, and 0.78 µM for the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ for S. cerevisiae. The mechanism of action underlying the death of these yeasts when exposed to these synergistic combinations involves several processes, including the loss of cell wall integrity, impairment of mitochondrial functionality, DNA condensation, and damage to cell morphology and ultrastructure. The data presented in this study will contribute significantly to the development of new therapies involving combinations of antifungal molecules.
Related
- A non-GMO Saccharomyces cerevisiae × Saccharomyces paradoxus brewing hybrid moderately reduces ethanol production and modifies beer aroma
- Multicellularity and virulence in the budding yeast, Saccharomyces cerevisiae
- The Linker Histone Plays a Dual Role during Gametogenesis in Saccharomyces cerevisiae
- A high-throughput genetic screening protocol to measure lipid bilayer stress-induced unfolded protein response in Saccharomyces cerevisiae
- Characterisation of Saccharomyces cerevisiae and Saccharomyces jurei hybrids for oenological applications
BibTeX
@article{souza2026vitro,
title = {{In Vitro Activity and Synergism of Amphotericin B and the Synthetic Bioinspired Peptide γ31-45PvD₁⁺⁺ Against Fungal Study Models Candida tropicalis and Saccharomyces cerevisiae.}},
author = {Thaynã A M Souza and Érica de O Mello and Fernanda G Trindade and Felipe F Moreira and Gabriel B Taveira and Milena B Cherene and Larissa M Resende and Sérgio H Seabra and Maura da Cunha and André de O Carvalho and Valdirene M Gomes},
journal = {Current microbiology},
year = {2026},
month = oct,
doi = {10.1007/s00284-026-05197-2},
url = {https://europepmc.org/article/MED/42905331},
note = {CC BY},
}
RIS
TY - JOUR
TI - In Vitro Activity and Synergism of Amphotericin B and the Synthetic Bioinspired Peptide γ31-45PvD₁⁺⁺ Against Fungal Study Models Candida tropicalis and Saccharomyces cerevisiae.
AU - Thaynã A M Souza
AU - Érica de O Mello
AU - Fernanda G Trindade
AU - Felipe F Moreira
AU - Gabriel B Taveira
AU - Milena B Cherene
AU - Larissa M Resende
AU - Sérgio H Seabra
AU - Maura da Cunha
AU - André de O Carvalho
AU - Valdirene M Gomes
PY - 2026
DA - 2026/10/21
JO - Current microbiology
DO - 10.1007/s00284-026-05197-2
UR - https://europepmc.org/article/MED/42905331
AB - In recent years, following the COVID-19 pandemic, the emergence of antibiotic-resistant microorganisms has increased. This surge has prompted global research into new biologically active molecules, particularly those focused on combination therapies involving antifungal agents. Synthetic antimicrobial peptides have emerged as promising candidates to address this demand. Therefore, the objective of this study was to assess the synergistic therapeutic effects of the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ combined with amphotericin B (AmB) on Candida tropicalis and Saccharomyces cerevisiae. This study aimed to identify the synergistic concentration that could facilitate advancement in the development of novel drugs. Here, we demonstrated that synergistic combinations of synthetic peptides and amphotericin B (AmB) effectively induce cell death in C. tropicalis and S. cerevisiae. The checkerboard test revealed synergistic concentrations of 0.048 µM for AmB, 0.39 µM for the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ for C. tropicalis, 0.097 µM for AmB, and 0.78 µM for the synthetic peptide γ₃₁₋₄₅PvD₁⁺⁺ for S. cerevisiae. The mechanism of action underlying the death of these yeasts when exposed to these synergistic combinations involves several processes, including the loss of cell wall integrity, impairment of mitochondrial functionality, DNA condensation, and damage to cell morphology and ultrastructure. The data presented in this study will contribute significantly to the development of new therapies involving combinations of antifungal molecules.
SN - 0343-8651
SN - 1432-0991
ER -